Focused On-demand Library for Glucose 1,6-bisphosphate synthase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

PMMLP; Phosphoglucomutase-2-like 1

Alternative UPACC:

Q6PCE3; Q96MQ7; Q9UIK3


Glucose 1,6-bisphosphate synthase, also known as Phosphoglucomutase-2-like 1 (PMMLP), plays a pivotal role in glucose metabolism. It catalyzes the synthesis of glucose 1,6-bisphosphate from 1,3-bisphosphoglycerate, impacting various sugars including glucose 1-phosphate and mannose 1-phosphate. Despite its low phosphopentomutase and phosphoglucomutase activity, its primary function is crucial for cellular energy management.

Therapeutic significance:

The protein is linked to a neurodevelopmental disorder characterized by developmental delay, dysmorphic facial features, and skin abnormalities. Understanding the role of Glucose 1,6-bisphosphate synthase could open doors to potential therapeutic strategies for this disorder, highlighting its significance in medical research.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.